Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Remix Therapeutics, Inc.

Home Clinical Trial Sponsors and OrganizationsRemix Therapeutics, Inc.

Remix Therapeutics, Inc.

ACTIVE

马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.remixtx.comHolding51–100 employeesEstablished: 2019-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2019

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

100.0%

Trial Status Distribution

Active, not recruiting

2

50.0%

Recruiting

1

25.0%

Suspended

1

25.0%

Clinical Trials

Trials sponsored by this organization (4)

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

20 participants

A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma.

30 participants

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

Active, not recruiting

Mar 2024100 participants

A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma.

Active, not recruiting

Jan 202480 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations